TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
←

venki ramakrishnan

T2 · manager / operator

Venki Ramakrishnan shared the 2009 Nobel Prize in Chemistry for ribosome structure work, served as President of the Royal Society (2015-2020), and authored 'Why We Die: The New Science of Aging and the Quest for Immortality'.

2 calls·2 names·0% bull·last heard 20 days ago·In Good Company with Nicolai Tangen
track record

no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY

top calls

highest conviction · one per company
1stmedium conviction
$ISOMORPHIC-LABSIsomorphic Labs

Demis Hassabis's Isomorphic Labs overoptimistic on AI eliminating all disease in 10-15 years

While AlphaFold revolutionized protein structure prediction, translating AI insights into actual treatments requires navigating the analog world of clinical trials, manufacturing, and regulation — a far slower process than digital innovation.

In Good Company with Nicolai Tangen2026-07→
2ndlow conviction
$ALTOS-LABSAltos Labs

Nobel laureate skeptical of Altos Labs' reprogramming approach for human longevity

Altos Labs has hired top scientists with massive funding ($5B) to pursue cellular reprogramming, but the approach faces major hurdles: heterogeneous reprogramming in tissues, oncogene risks, delivery challenges, and unproven lifespan extension even in mice.

In Good Company with Nicolai Tangen2026-07→

most discussed · click a bar to filter

recurring themes

2 total
$ISOMORPHIC-LABS
Isomorphic Labs
MEDvenki ramakrishnan·In Good Company with Nicolai Tangen·20 days ago
Demis Hassabis's Isomorphic Labs overoptimistic on AI eliminating all disease in 10-15 years
While AlphaFold revolutionized protein structure prediction, translating AI insights into actual treatments requires navigating the analog world of clinical trials, manufacturing, and regulation — a far slower process than digital innovation.
"I actually know Demis quite well and in fact he asked me to be on the advisory board of one of his companies, Isomorphic Labs and I think he's a brilliant guy. However, I would sa…"
16:50
$ALTOS-LABS
Altos Labs
LOWvenki ramakrishnan·In Good Company with Nicolai Tangen·20 days ago
Nobel laureate skeptical of Altos Labs' reprogramming approach for human longevity
Altos Labs has hired top scientists with massive funding ($5B) to pursue cellular reprogramming, but the approach faces major hurdles: heterogeneous reprogramming in tissues, oncogene risks, delivery challenges, and unproven lifespan extension even in mice.
"I think they're their bet is if we hire some top scientists they will come up with useful stuff that then we can monetize in the longevity business. And so that's a clear, you kno…"
22:00